Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7530437 | 0.82 | FFAR4 (0.42) | — | |
| SCHEMBL7522247 | 0.77 | FFAR4 (0.41) | RXRARXRBRXRG | |
| SCHEMBL7184297 | 0.77 | KDM4E (0.44) | RXRA | |
| SCHEMBL16423275 | 0.75 | ALDH1A1 (0.43) | ADRB3ADRB1MKNK1MKNK2 | |
| SCHEMBL2770553 | 0.75 | ADRB3 (0.43) | ADRB3ADRB1 | |
| SCHEMBL14860053 | 0.75 | MTNR1A (0.45) | — | |
| SCHEMBL28428155 | 0.74 | CYP4F2 (0.42) | RXRA | |
| SCHEMBL1851002 | 0.74 | CA12 (0.56) | RXRARXRB | |
| SCHEMBL283 | 0.74 | SLC6A3 (0.48) | — | |
| SCHEMBL1852479 | 0.73 | SLC7A5 (0.49) | RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486141-B2 | TREATING OR PREVENTING PTP-1B MEDIATED DISEASES, INCLUDING DIABETES, OBESITY, AND DIABETES-RELATED CONDITIONS. | MERCK FROSST CANADA & CO. (CA) | 2002-11-26 | — | — | US | disclosed |
| EP-1244677-A1 | PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| US-20020052346-A1 | Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | MERCK FROSST CANADA LTD. (CA) | 2002-05-02 | — | — | US | disclosed |
| WO-2001046203-A1 | PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052346-A1 | Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | PTPRO, PPM1B, PTPA | ADRB3 3081/4885ADRB1 2380/4885RXRA 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.